Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4484-4493

  Kleijn, Anne ^a,b   Chen, John W ^a   Buhrman, Jason S ^a   Wojtkiewicz, Gregory R ^a   Iwamoto, Yoshiko ^a   Lamfers, Martine L ^b   Stemmer Rachamimov, Anat O ^a   Rabkin, Samuel D ^a   Weissleder, Ralph ^a   Martuza, Robert L ^a   Fulci, Giulia ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GADOLINIUM; GADOLINIUM PENTETATE; MYELOPEROXIDASE; ONCOLYTIC VIRUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL INFILTRATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; GLIOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOCOMPETENT CELL; IN VIVO STUDY; INFLAMMATION; INTRATUMORAL INFLAMMATION; MALE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERITUMORAL INFLAMMATION; PRIORITY JOURNAL; RAT; TUMOR VOLUME;

ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; EDEMA; GENETIC VECTORS; INFLAMMATION; KINETICS; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; PEROXIDASE; RATS; RATS, INBRED F344;

EID: 79960318983     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0575     Document Type: Article

References (48)

1. Auf G, Carpentier AF, Chen L, Le Clanche C, Delattre JY. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin Cancer Res 2001;7:3540-3. (Pubitemid 33069992)
2. Castriconi R, Daga A, Dondero A, Zona G, Poliani PL, Melotti A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 2009;182:3530-9.
3. Chang GH, Barbaro NM, Pieper RO. Phosphatidylserine-dependent phagocytosis of apoptotic glioma cells by normal human microglia, astrocytes, and glioma cells. Neuro Oncol 2000;2:174-83.
4. Friese MA, Steinle A, Weller M. The innate immune response in the central nervous system and its role in glioma immune surveillance. Onkologie 2004;27:487-91. (Pubitemid 39664164)
5. Graf MR, Jadus MR, Hiserodt JC, Wepsic HT, Granger GA. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J Immunol 1999;163:5544-51.
6. Graf MR, Prins RM, Merchant RE. IL-6 secretion by a rat T9 glioma clone induces a neutrophil-dependent antitumor response with resultant cellular, antiglioma immunity. J Immunol 2001;166:121-9. (Pubitemid 32038424)
7. Nickles D, Abschuetz A, Zimmer H, Kees T, Geibig R, Spiess E, et al. End-stage dying glioma cells are engulfed by mouse microglia with a strain-dependent efficacy. J Neuroimmunol 2008;197:10-20.
8. Wallace PK, Romet-Lemonne JL, Chokri M, Kasper LH, Fanger MW, Fadul CE. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol Immunother 2000;49:493-503.
9. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124: 263-6. (Pubitemid 43121975)
10. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-7. (Pubitemid 36019639)
11. de Visser KE, Korets LV, Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005;7:411-23. (Pubitemid 40719125)
12. Hussain SF, Yang D, Suki D, Grimm E, Heimberger AB. Innate immune functions of microglia isolated from human glioma patients. J Transl Med 2006;4:15.
13. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NFkappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 2009;139:693-706.
14. Markovic DS, Glass R, Synowitz M, Rooijen N, Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J Neuropathol Exp Neurol 2005; 64:754-62. (Pubitemid 41285807)
15. Morandi E, Zingaretti C, Chiozzotto D, Severini C, Semeria A, Horn W, et al. A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. Cancer Lett 2006;231:74-86. (Pubitemid 41779455)
16. Morimura T, Neuchrist C, Kitz K, Budka H, Scheiner O, Kraft D, et al. Monocyte subpopulations in human gliomas: expression of Fc and complement receptors and correlation with tumor proliferation. Acta Neuropathol (Berl) 1990;80:287-94. (Pubitemid 20220544)
17. Synowitz M, Glass R, Färber K, Markovic D, Kronenberg G, Herrmann K, et al. A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 2006;66:8550-7. (Pubitemid 44449168)
18. Friedman A, Tian JP, Fulci G, Chiocca EA, Wang J. Glioma virotherapy: effects of innate immune suppression and increased viral replication capacity. Cancer Res 2006;66:2314-9.
19. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, et al. Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A 2006;103:12873-8. (Pubitemid 44298654)
20. Fulci G, Dmitrieva N, Gianni D, Fontana EJ, Pan X, Lu Y, et al. Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res 2007;67:9398-406.
21. Kurozumi K, Hardcastle J, Thakur R, Yang M, Christoforidis G, Fulci G, et al. Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy. J Natl Cancer Inst 2007;99:1768-81. (Pubitemid 351767207)
22. Lamfers ML, Fulci G, Gianni D, Tang Y, Kurozumi K, Kaur B, et al. Cyclophosphamide increases transgene expression mediated by an oncolytic adenovirus in glioma-bearing mice monitored by bioluminescence imaging. Mol Ther 2006;14:779-88. (Pubitemid 44743132)
23. Wakimoto H, Fulci G, Tyminski E, Chiocca EA. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004;11:214-23. (Pubitemid 38159694)
24. Arnhold J, Flemmig J. Human myeloperoxidase in innate and acquired immunity. Arch Biochem Biophys; 500:92-106.
25. Saran M, Beck-Speier I, Fellerhoff B, Bauer G. Phagocytic killing of microorganisms by radical processes: consequences of the reaction of hydroxyl radicals with chloride yielding chlorine atoms. Free Radic Biol Med 1999;26:482-90. (Pubitemid 29013481)
26. Breckwoldt MO, Chen JW, Stangenberg L, Aikawa E, Rodriguez E, Qiu S, et al. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci U S A 2008;105:18584-9.
27. Chen JW, Pham W, Weissleder R, Bogdanov A Jr. Human myeloperoxidase: a potential target for molecular MR imaging in atherosclerosis. Magn Reson Med 2004;52:1021-8. (Pubitemid 39453274)
28. Nahrendorf M, Sosnovik D, Chen JW, Panizzi P, Figueiredo JL, Aikawa E, et al. Activatable magnetic resonance imaging agent reports myeloperoxidase activity in healing infarcts and noninvasively detects the antiinflammatory effects of atorvastatin on ischemia-reperfusion injury. Circulation 2008;117:1153-60. (Pubitemid 351552019)
29. Querol M, Chen JW, Weissleder R, Bogdanov A Jr. DTPA-bisamide-based MR sensor agents for peroxidase imaging. Org Lett 2005;7: 1719-22. (Pubitemid 40685347)
30. Rodriguez E, Nilges M, Weissleder R, Chen JW. Activatable magnetic resonance imaging agents for myeloperoxidase sensing: mechanism of activation, stability, and toxicity. J Am Chem Soc 2010;132:168-77.
31. + myeloid cells infiltrate allografts and contribute to an imaging signature of organ rejection in mice. J Clin Invest 2010;120:2627-34.
32. Ronald JA, Chen JW, Chen Y, Hamilton AM, Rodriguez E, Reynolds F, et al. Enzyme-sensitive magnetic resonance imaging targeting myeloperoxidase identifies active inflammation in experimental rabbit atherosclerotic plaques. Circulation 2009;120:592-9.
33. Chen JW, Breckwoldt MO, Aikawa E, Chiang G, Weissleder R. Myeloperoxidase-targeted imaging of active inflammatory lesions in murine experimental autoimmune encephalomyelitis. Brain 2008;131: 1123-33. (Pubitemid 351499418)
34. Chen JW, Querol Sans M, Bogdanov A Jr, Weissleder R. Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 2006;240:473-81. (Pubitemid 44098644)
35. Goldstein DJ, Weller SK. An ICP6::lacZ insertional mutagen is used to demonstrate that the UL52 gene of herpes simplex virus type 1 is required for virus growth and DNA synthesis. J Virol 1988;62:2970-7.
36. Wakimoto H, Johnson PR, Knipe DM, Chiocca EA. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells. Gene Ther 2003;10:983-90. (Pubitemid 36722433)
37. Marsh J, Mukherjee P, Seyfried TN. Akt-dependent proapoptotic effects of dietary restriction on late-stage management of a phosphatase and tensin homologue/tuberous sclerosis complex 2-deficient mouse astrocytoma. Clin Cancer Res 2008;14:7751-62.
38. Kettle AJ, Gedye CA, Hampton MB, Winterbourn CC. Inhibition of myeloperoxidase by benzoic acid hydrazides. Biochem J 1995;308: 559-63.
39. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009;325:612-6.
40. Chiocca EA, Abbed KM, Tatter S, Louis DN, Hochberg FH, Barker F, et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther 2004;10:958-66. (Pubitemid 39419921)
41. Moore A, Weissleder R, Bogdanov A Jr. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging 1997;7:1140-5. (Pubitemid 28372892)
42. Van Der Veen BS, de Winther MP, Heeringa P. Myeloperoxidase: molecular mechanisms of action and their relevance to human health and disease. Antioxid Redox Signal 2009;11:2899-937.
43. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002;72:101-6.
44. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005;5:953-64. (Pubitemid 41746764)
45. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007;204:3037-47. (Pubitemid 350179569)
46. Sunderk€otter C, Nikolic T, Dillon MJ, Van Rooijen N, Stehling M, Drevets DA, et al. Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response. J Immunol 2004;172:4410-7. (Pubitemid 38375256)
47. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, et al. The case of oncolytic viruses vs the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009;20:1119-32.
48. Stanford MM, Breitbach CJ, Bell JC, McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr Opin Mol Ther 2008;10:32-7.